Ivermectin Mass Drug Administration

Ivermectin mass drug administration to reduce malaria transmission in Surat Thani: a cluster randomized trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210219009

Enrollment

6700

Registered

2021-02-19

Start date

2021-02-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malaria malaria transmission ivermectin

Interventions

Ivermectin mass drug administration, monthly treatment for 3 consecutive months, 200-400 microgram/kg dose,No treatment control

Experimental Drug,No Intervention No treatment

Treatment,Control

Eligibility

Sex/Gender

All

Age

6 Months to No maximum

Inclusion criteria

Inclusion criteria: 1. Thai people, both male and female 2. Aged > 6 months for mass blood survey to determine malaria infection 3. Aged between 5 - 80 years for ivermectin administration

Exclusion criteria

Exclusion criteria: For participation in MDA: 1. Weighing less than 15 kilograms 2. Body Temperature > 37.5 oC 3. Not available for follow-up 4. Known hypersensitivity or anaphylaxis to Ivermectin 5. Known active hepatitis or renal disease 6. Pregnant or lactating women or planning to become pregnant during MDA

Design outcomes

Primary

Measure	Time frame
Infection immediately before drug administration (month 0), during drug administration at month (months 1,2), after drug administration (months 3,4) prevalence	—

Secondary

Measure	Time frame
Infection two months after drug administration period prevalence	—

Countries

Thailand

Contacts

Public ContactJetsumon Prachumsri

Mahidol University

jetsumon.pra@mahidol.edu023069187

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026